Klinische Studien Radar

Prior treatment with ianalumab

History of receiving following treatment: I) high dose CS, calcineurin inhibitors, JAK or other kinase inhibitors or other DMARD (except as listed in inclusion criteria) administered within 12 weeks prior to screening. II) cyclophosphamide or biologics such as immunoglobulins (intravenous or s.c.), plasmapheresis, anti-type I interferon receptor biologic agents, anti-CD40 agents, CTLA4-Fc Ig or B-cell activating factor (BAFF)-targeting agents administered within 24 weeks prior to screening; belimumab administered within 12 weeks prior to screening. III) any B cell-depleting therapies, other than ianalumab administered within 36 weeks prior to randomization or as long as B cell count is less than the lower limit of normal or baseline value prior to receipt of B cell-depleting therapy (whichever is lower). IV) Traditional Chinese medicines administered within 30 days prior to randomization.

Active viral, bacterial or other infections requiring intravenous or intramuscular treatment for clinically significant infection

Chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)

Evidence of active tuberculosis infection

History of primary or secondary immunodeficiency, including a positive human immunodeficiency virus (HIV) test result at screening

Any one of the following abnormal laboratory values prior to randomization

• Platelets < 25000/mm^3 (< 25 x 10^3/μL)
• Hemoglobin (Hgb) < 8.0 g/dL (< 5 mmol/L), or < 7.0 g/dL (< 4.3 mmol/L) if related to participant's SLE such as in active hemolytic anaemia
• Absolute neutrophil count (ANC) (< 0.8 x 10^3/ μL)

Severe organ dysfunction or life-threatening disease at screening

Presence of severe lupus kidney disease as defined by proteinuria above 2 g/day or equivalent using spot urine protein creatinine ratio, or serum creatinine greater than 2.0 mg/dL (176.84 µmol/L), or requiring immune-suppressive induction or maintenance treatment at screening

Receipt of live/attenuated vaccine within a 4-week period before first dosing

Any uncontrolled, co-existing serious disease, which in the opinion of the investigator will place the participant at risk for participation or interfere with evaluation for SLE-related symptoms

Non-lupus conditions such as asthma, gout or urticaria, requiring intermittent or chronic treatment with systemic CS

History of malignancy of any organ system other than localized basal cell carcinoma of the skin or in situ cervical cancer

Pregnant or nursing (lactating) women.

Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception while on study treatment and for 6 months after stopping of investigational drug.

Any surgical, medical, psychiatric or additional physical condition that may jeopardize participation in this study